Company News: Dyax, Teva and Shire
Dyax received FDA approval for Kalbitor (ecallantide/DX-88) for treating acute attacks of hereditary angioedema (HAE), a rare, genetic disorder.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.